Biomagi

Biomagi is a Slovakia-based, medicinal chemistry-focused biotechnology company and contract research organization founded in 2010. The company specializes in the rational and rapid development of novel preclinical drug candidates using its proprietary virtual high-throughput screening platform, which queries a database of over 8.7 million diverse organic structures. Biomagi designs and optimizes small molecule inhibitors targeting key biological pathways, including VEGFR2, CLK1, PFKFB3, and ALR2, to address oncology, cancer stem cells, and diabetic complications. By utilizing structure-based drug design and computer predictions, the company identifies and validates drug-like compounds for biological screening without the immediate need for time-consuming synthesis.